Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | DRD4 | P21917 | 4/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.35 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290250 | 0.93 | CNR2 (0.46) | HTR1ADRD2DRD4CNR2KCNH2 | |
| SCHEMBL3466225 | 0.83 | GPR119 (0.48) | TRPV3THRBGAASMN1; SMN2 | |
| SCHEMBL3468098 | 0.82 | SCN4A (0.42) | HTR1ADRD2DRD4THRBGAA | |
| SCHEMBL3467760 | 0.82 | KDM4E (0.44) | HTR1ADRD2DRD4CNR2KCNH2 | |
| Water SCHEMBL3474017 | 0.81 | KDM4E (0.43) | HTR1ADRD2DRD4CNR2KCNH2 | |
| SCHEMBL4299114 | 0.79 | CNR2 (0.46) | HTR1ADRD2DRD4CNR2PARP1 | |
| SCHEMBL412412 | 0.78 | CNR2 (0.49) | HTR1ADRD2DRD4CNR2KCNH2 | |
| SCHEMBL3467466 | 0.77 | CNR2 (0.42) | CNR2PARP1 | |
| SCHEMBL1557415 | 0.76 | TRPV3 (0.48) | CNR2TRPV3THRB | |
| SCHEMBL31186133 | 0.75 | CYP1A2 (0.57) | HTR1ADRD2DRD4CNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | HTR6, HTR5A, TPH1 | HTR1A 4/4885DRD2 93/4885DRD4 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.